Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class ASZSE: 002773

Chengdu Kanghong: US FDA Approves KHN921 Clinical Trial For Hypertrophic Cardiomyopathy Treatment

· Issued by Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A

Chengdu Kanghong Pharmaceutical Group Co Ltd SZSE:002773:

  • US FDA APPROVES CLINICAL TRIAL OF KHN921 FOR HYPERTROPHIC CARDIOMYOPATHY TREATMENT

Company analysis